Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs NuBloom

Medro
Graded #256

Lower grade

vs+5.399999999999999
NuBloom
Graded #139

Higher grade

The verdict

NuBloom takes it — 69/100 to 63.6/100.

NuBloom grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuBloom is a women's metabolic-health telehealth practice founded by family and integrative-medicine physician Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuBloom +22
50
72
Dose & formulationMedro +23
77
54
Clinical oversightNuBloom +11
71
82
Labs & monitoringNuBloom +9
52
61
FulfillmentMedro +7
92
85
Contract termsNuBloom +22
33
55
Medro · left barNuBloom · right bar

The numbers

MetricMedroNuBloom
WeighScore63.6/10069/100
GradeCC
Scorecard rank#256#139
Semaglutide$199/mo (compounded)$149/mo (2.4 mg dose, compounded)
Tirzepatide$299/mo (compounded)$279/mo (15 mg dose, compounded)
CoverageAll 50 states49 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
NuBloom

Graded #139 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard